Increased glutathione levels and activity of PON1 (phenyl acetate esterase) in the liver of rats after a single dose of cyclophosphamide: A defense mechanism?

Experimental and Toxicologic Pathology

Volumn 59, Issue 5, 2008, Pages 301-306

  Abraham, Premila ^a   Sugumar, Emila ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Cyclophosphamide; Glutathione; Liver; Paraoxonase; Rat

Indexed keywords

ALANINE AMINOTRANSFERASE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; CYCLOPHOSPHAMIDE; GLUTATHIONE; LIPID; MALONALDEHYDE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BIOCHEMISTRY; BODY WEIGHT; CONTROLLED STUDY; DEFENSE MECHANISM; DRUG ACTIVATION; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; LIPID PEROXIDATION; LIVER INJURY; LIVER PROTECTION; LIVER TOXICITY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RAT;

RATTUS; RATTUS NORVEGICUS;

EID: 39649088017     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etp.2007.06.006     Document Type: Article

References (34)

1. Abraham P., Kanakasabapathy I., and Sugumar E. Decrease in the activities of lysosomal enzymes may contribute to the urotoxicity of cyclophosphamide in the rat. Biomed Res 18 (2007) 131-136
2. Ahluwalia A., Maggi C.A., Santiccioli P., Lecci A., and Giuliani S. Characterisation of the capsaicin-sensitive component of cyclophosphamide-induced inflammation in the rat urinary bladder. Br J Pharmacol 111 (1994) 1017-1022
3. Ciralik H., Bulbuloglu M.D., Centinkaya A., Kurutas E.B., Celik M., and Polat A. Effects of N acetylcysteine on methotrexate-induced small intestinal damage. Mount Sinai J Med 73 (2006) 1086-1092
4. Dollery A. Cyclophosphamide. In: Dollery C., (Ed). Therapeutic drugs (1999), Churchill Livingstone, Edinburgh 349-353
5. Eckerson H.W., Wyte C.M., and La Du B.N. The human serum paraoxonase/aryl esterase polymorphism. Am J Hum Genet 35 (1983) 1126-1138?
6. Ellman G.L. Tissue sulphydryl groups. Arch Biochem Biophys 82 (1959) 70-77
7. Fang Y.Z., Yang S., and Wu G. Free radicals, antioxidants, and nutrition. Nutrition 18 (2002) 872-879 (review)
8. Ferre N., Camps J., Cabre M., Paul A., and Joven J. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 50 (2001) 997-1000
9. Gil F., Pla A., and Gonzalvo M C. Rat liver paraoxonase: subcellular distribution and characterization. Chem Biol Intereact 87 (1993) 149-153
10. Gonzalvo M.C., Gil F., and Hernandez a.F. Human liver paraoxonase (PON1): subcellular distribution and characterization. J Biochem Mol Toxicol 12 (1998) 61-69
11. Gustafsson L.L., Eriksson L., and Dahl S. Eleborg L cyclophosphamide induced acute liver failure requiring transplantation in a patient with genetically deficient debrisoquine metabolism: a causal relationship?. J Int Med 240 (1996) 311-314
12. Haque R., Bin-Hafeez B., Parvez S., and Pandey S. Aqueous extract of walnut (Juglans regia L.) protects mice against cyclophosphmide induced biochemical toxicity. Human Exp Toxicol 22 (2003) 473-480
13. Higashino K., Takahashi Y., and Yamamura Y. Release of phenyl acetate esterase from liver microsomes by carbon tetrachloride. Clin Chim Acta 41 (1972) 313-320
14. Jaouad L., Milochevitch C., and Khalil A. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant property. Free Radic Res 37 (2003) 77-83
15. Kopecna L. Late effects of anticancer therapy on kidney function in children with acute lymphoblastic leukemia. Bratisl Lek Listy 102 (2001) 357-360
16. La Du B.N. Human serum paraoxonase/arylesterase. In: Kalow W., (Ed). Pharmacogenetics of drug metabolism (1992), Pergamon, New York, 51-91
17. La Du B.N. Structural and functional diversity of paraoxonases. Nat Med 2 (1996) 1186-1187
18. Lowry O.H., Rosebrough M.J., and Farr A.L. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
19. Mackness M.I., and Durrington P.N. HDL, its enzyme and its potential to influence lipid peroxidation. Atherosclerosis 115 (1995) 243-253
20. Mackness M.I., Mackness B., and Durrington P.N. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 7 (1996) 69-76
21. Manda K., and Bhatia A.L. Prophylactic action of melatonin against cyclophosphamide induced oxidative stress in mice. Cell Biol Toxicol 19 (2003) 367-372
22. Nguyen S.D., and Sok D.E. Oxidative inactivation of paraoxonase 1, an antioxidant protein and its effect on antioxidant action. Free Radic Res 37 (2003) 1319-1330
23. Ohkawa H., Oshini N., and Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric reaction. Ann Biochem 95 (1979) 351-358
24. Reitman S., and Frankel S. Colorimetric method for the determination of serum glutamic-oxaloacetic and glutamic pyruvic transaminases. Am J Clin Pathol 28 (1957) 56-63?
25. Rosenberg O., Rosenblat M., and Coleman R. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1 knockout mice. Free Radic Biol Med 34 (2003) 774-784
26. Roy P., and Waxman D.J. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Toxicol In Vitro 20 (2006) 176-186
27. Shaunak S., Munro J.M., Weinbren K., Walport M.J., and Cox T.M. Cyclophosphamide-induced liver necrosis: a possible interaction with azathioprine. Q J Med 67 (1988) 309-317
28. Sugumar E., Indirani K., and Abraham P. Normal plasma creatinine levels despite histological evidence of renal damage in cyclophosphamide treated rats. Clin Chim Acta 376 (2007) 244-245
29. Townsend D.M., Tew K.D., and Tapiero H. The importance of glutathione in human disease. Biomed Pharmacother 57 (2003) 145-155 (review)
30. Takahashi Y., Aoyama F., Ito F., and Yamamura Y. Evaluation of phenyl acetate esterase activity as an index of liver damage. Clin Chim Acta 18 (1967) 21-32
31. Tsai-Turton M., Luong B.T., Tan Y., and Luderer U. Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion. Toxicol Sci (2007) April 13 [Epub ahead of print]
32. Tsuzura S., Ikeda Y., and Suchiro Y. Correlation of plasma oxidized low density lipoprotein levels to vascular complications and human serum paraoxonase in patients with Type 2 diabetes. Metabolism 53 (2004) 297-302
33. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96 (1995) 2882-2891
34. Walker R.D., and Sommerkamp H. Hemorrhagic cystitis after high dose chemotherapy. An interdisciplinary problem. Urologie A 37 (1998) 516-521